Superdrol

Methyl Drostanolone 10mg

$79.99

Product Name: SUPERDROL
Strength per Capsule: 10 mg Methasterone (Methyldrostanolone)
Capsules per card: 24 vegetarian capsules
Other Names: Methasterone; Methyldrostanolone; Methasteron; “Superdrol”; 2α,17α-dimethyl-5α-androstan-17β-ol-3-one; 2α,17α-dimethyl-DHT
CAS Number: 3381-88-2
Molecular Formula / Weight: C₂₁H₃₄O₂ / 318.50 g·mol⁻¹
Chemical Class: 17α-alkylated oral anabolic-androgenic steroid (AAS), dimethylated DHT derivative:contentReference[oaicite:1]{index=1}.

Important Chemistry Note: 

The 17α-alkyl group enables oral bioavailability but is associated with cholestatic liver injury risk. SUPERDROL is strictly for lawful research or analytical use; not an approved medicine or dietary supplement.

10 Strong Points & Benefits (Evidence-Informed)

  1. Potent anabolic activity in preclinical models via androgen receptor (AR) activation in muscle and bone.

  2. 17α-alkylation allows measurable oral bioavailability suitable for pharmacokinetic sampling.

  3. Non-aromatizable DHT-derived structure eliminates estrogenic side effects like gynecomastia or fluid retention.

  4. Low mineralocorticoid and progestational activity improves AR-specific selectivity.

  5. Produces high signal-to-noise biomarker shifts (rapid HDL reduction, LH/testosterone suppression, liver enzyme changes) valuable in research pharmacodynamics.

  6. Metabolites are well-characterized, supporting LC-MS/MS detection and anti-doping analyses.

  7. Classified under WADA S1 “Anabolic Agents,” simplifying compliance and exclusion criteria in sport-related research.

  8. Widely cited in toxicology studies for modeling cholestatic hepatotoxicity (BSEP inhibition, canalicular transport research).

  9. Legally defined Schedule III anabolic steroid under the U.S. Controlled Substances Act.

  10. Paragon Pharmatech ensures GMP-grade, CoA-verified product labeling and documentation for research integrity.

Overview:

SUPERDROL (methasterone) is a synthetic, non-aromatizable anabolic steroid derived from dihydrotestosterone (DHT). Its 17α-methyl substitution enhances oral stability, while the 2α-methyl group increases anabolic potency relative to DHT analogs. These properties make it a valuable model for androgen-receptor signaling and hepatotoxicity studies:contentReference[oaicite:2]{index=2}.

How It Works (Mechanism & Pharmacology)

  1. Androgen Receptor Activation: Methasterone binds AR in skeletal muscle and bone, stimulating transcription of anabolic genes (myosin heavy chain, IGF-1) while repressing catabolic pathways (ubiquitin–proteasome system).

  2. Non-Aromatizing DHT Lineage: Being 5α-reduced and non-aromatizable, it exerts effects exclusively through AR without conversion to estrogens or DHT intermediates.

  3. Pharmacokinetics: The 17α-methyl group protects against first-pass hepatic metabolism, yielding detectable systemic exposure after oral dosing; estimated half-life 8–12 hours.

  4. Endocrine Feedback: Suppresses hypothalamic–pituitary–gonadal (HPG) activity (↓ GnRH, LH, FSH, endogenous testosterone) during exposure; recovery requires post-cycle evaluation.

  5. Cardiometabolic Effects: 17α-alkylated AAS classically reduce HDL, raise LDL, increase hematocrit, and elevate BP—necessitating lipid and hepatic monitoring.

What Studies Have Shown

Clinicopathologic Hepatotoxicity Series

Multiple case reports describe cholestatic hepatitis after methasterone exposure with jaundice, elevated bilirubin, and minimal transaminase elevation. Liver biopsies reveal canalicular cholestasis and minimal inflammation. Most recovered after discontinuation; some developed acute renal injury or coagulopathy:contentReference[oaicite:3]{index=3}.

LiverTox & Toxicology Reviews

NIH LiverTox lists methasterone among high-risk oral AAS for cholestatic liver injury and rare hepatic neoplasms with prolonged use:contentReference[oaicite:4]{index=4}.

Regulatory & Anti-Doping Actions

WADA classifies methasterone as an anabolic agent (S1). The U.S. DEA schedules it as a controlled anabolic steroid (Schedule III). FDA enforcement actions removed methasterone-containing supplements from market in 2006:contentReference[oaicite:5]{index=5}.

Class Effects — Lipid & Endocrine Changes

Oral AAS, including methasterone, suppress HDL-C, elevate LDL-C, and reduce LH/testosterone with varying reversibility. These features inform its use as a model compound for endocrine and hepatic safety frameworks:contentReference[oaicite:6]{index=6}.

Evidence Summary

  • Strongest: Human hepatotoxicity case reports and regulatory documentation.

  • Mechanistic Support: AR-driven anabolic signaling, 17α-alkylation explaining oral potency and hepatic risk.

  • Gaps: No controlled human efficacy trials; limited preclinical comparative data versus drostanolone or oxymetholone.

Usage & Quality Compliance

SUPERDROL is produced under GMP-aligned conditions for lawful research, analytical, or educational use only. Not for medical or dietary consumption.

  • Identity: Verified via LC-MS/MS, NMR spectral matching.

  • Assay: 10 mg ±5% per capsule.

  • Purity: Residual solvents, related steroids, and metals within ICH Q3D limits.

  • Microbial: Tested for bioburden and endotoxin.

  • Labeling: Tamper-evident, lot-coded, with “For Research Use Only.”

  • Storage: Cool, dry, dark conditions; protect from moisture.

Protocol Design Guidance

  • Baseline screening: liver function (ALT, AST, ALP, bilirubin), lipids, CBC, hormones (LH, FSH, TT), and BP.

  • Monitor: repeat labs biweekly; stop for bilirubin >2× ULN or ALT/AST >3× ULN with symptoms.

  • Exclusions: liver/kidney disease, uncontrolled hypertension, androgen-sensitive neoplasia.

  • Avoid hepatotoxic co-medications (statins, azoles, isotretinoin, alcohol excess).

Safety Note

  • Status: Schedule III anabolic steroid; investigational only.

  • Liver Safety: High risk for cholestatic injury—monitor bilirubin, ALP, and clinical signs.

  • Cardiometabolic: Expect HDL suppression and BP elevation; manage via diet and monitoring.

  • Endocrine: Suppresses HPG axis; post-cycle recovery necessary.

  • Dermatologic/Psychiatric: Acne, mood shifts, or alopecia possible in predisposed individuals.

  • Pregnancy: Contraindicated; teratogenic and growth-inhibiting effects known for AAS class.

Disclaimer: For scientific and educational use only. Not for human therapy or supplementation.

Referenced Citations

  1. Shah NL et al., Clin Gastroenterol Hepatol. 2008. Methasteron-associated cholestatic liver injury (5 cases).

  2. U.S. DEA, Federal Register (2011): Classification of methasterone as Schedule III anabolic steroid.

  3. LiverTox (NIH): Androgenic steroids — hepatotoxicity and long-term risks.

  4. WADA Prohibited List 2025: S1 Anabolic Agents.

  5. Fontana K et al., Clin Sci. Adverse effects of anabolic-androgenic steroids.

  6. Washington Post, 2006: FDA enforcement against methasterone-containing supplements.

  7. Mil Med. 2016: Case literature—AAS-related DILI in deployed service members.

  8. MZCloud & PubChem: Methasterone spectral and structural data.